Emmaus Life Sciences (EMMA)
(Delayed Data from OTC)
$0.02 USD
0.00 (-9.09%)
Updated Sep 20, 2024 01:38 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Emmaus Life Sciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 30 | 18 | 21 | 23 | 23 |
Cost Of Goods | 1 | 3 | 3 | 2 | 1 |
Gross Profit | 28 | 16 | 17 | 21 | 22 |
Selling & Adminstrative & Depr. & Amort Expenses | 25 | 22 | 23 | 21 | 26 |
Income After Depreciation & Amortization | 4 | -7 | -6 | 0 | -5 |
Non-Operating Income | 0 | 1 | -7 | 7 | -23 |
Interest Expense | 7 | 5 | 3 | 6 | 28 |
Pretax Income | -4 | -11 | -16 | 1 | -55 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -4 | -11 | -16 | 1 | -55 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -4 | -11 | -16 | 1 | -55 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 6 | -5 | -4 | 4 | 19 |
Depreciation & Amortization (Cash Flow) | 3 | 2 | 2 | 4 | 24 |
Income After Depreciation & Amortization | 4 | -7 | -6 | 0 | -5 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 53.11 | 49.44 | 49.25 | 48.90 | 42.26 |
Diluted EPS Before Non-Recurring Items | -0.07 | -0.21 | -0.32 | 0.02 | -1.30 |
Diluted Net EPS (GAAP) | -0.07 | -0.21 | -0.32 | 0.02 | -1.30 |
Fiscal Year end for Emmaus Life Sciences, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 5.38 | 2.51 | 7.07 | 5.02 | 10.76 |
Cost Of Goods | 0.24 | 0.26 | 0.19 | 0.21 | 0.51 |
Gross Profit | 5.14 | 2.25 | 6.88 | 4.80 | 10.25 |
SG&A, R&D, and Dept/Amort Expenses | 4.55 | 4.99 | 5.53 | 4.78 | 6.93 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.59 | -2.74 | 1.35 | 0.02 | 3.32 |
Non-Operating Income | -1.77 | 0.30 | 1.62 | 1.99 | -3.05 |
Interest Expense | 0.97 | 1.91 | 2.18 | 1.91 | 1.79 |
Pretax Income | -2.15 | -4.36 | 1.10 | 0.11 | -1.52 |
Income Taxes | 0.03 | -0.01 | -0.11 | 0.04 | -0.03 |
Minority Interest | 0.00 | 0.00 | NA | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | NA | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | NA | 0.00 | 0.00 |
Income From Cont. Operations | -2.18 | -4.35 | 1.21 | 0.07 | -1.48 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -2.18 | -4.35 | 1.21 | 0.07 | -1.48 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 63.36 | 61.85 | 50.39 | 138.38 | 52.87 |
Diluted EPS Before Non-Recurring Items | -0.03 | -0.07 | 0.02 | -0.01 | -0.03 |
Diluted Net EPS (GAAP) | -0.03 | -0.07 | 0.04 | -0.01 | -0.03 |